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The Fas receptor belongs to the tumour necrosis factor (TNF)
family of receptors whose activation signals the cell to undergo
apoptosis (Nagata, 1997). Whereas Fas is ubiquitously expressed
in the body, Fas ligand (FasL) is expressed on activated T cells and
NK cells and serves an important function in the destruction of
virus-infected and transformed cells. Defects in the Fas/FasL
system lead to abnormal T cell development and lymphoprolifer-
ative disorders, demonstrating that apoptosis by Fas/FasL inter-
action is necessary for negative selection of T cells in the thymus 
and for keeping homeostasis of the peripheral immune system
(Nagata, 1997). 
Although first thought to be mostly expressed in activated T and
NK cells, FasL has been found in several other cell types, i.e.
epithelial cells and some tissues that enjoy a certain protection
from the cellular arm of the immune system. These ‘immune pri-
vileged’ sites include the eye and testis, organs that could suffer
irreversible damage if invaded by inflammatory cells (Bellgrau
et al, 1995; Griffith et al, 1995). Early reports, showing down-
regulated Fas expression and sensitivity in some human tumours
caused speculations that this could be a way for tumours to evade
killing by the immune system system (Strand et al, 1996). Further
supporting a potential role for the involvement of Fas and FasL in
tumour defence mechanisms, it was shown that some tumour cells
express FasL and are able to induce apoptosis in Fas-sensitive 
T-cell lines (Strand et al, 1996; Niehans et al, 1997). Since these
first studies were published, it has become clear that FasL is
expressed in normal epithelial cells and its role in the defence
of tumour cells against the immune system is far from being
established (Xerri et al, 1997). 
Breast tumours often contain large lymphocytic infiltrates that
seem to be unable to affect the growth of the surrounding malig-
nant cells (O’Sullivan and Lewis, 1994). This study was under-
taken to analyse the expression of Fas and FasL in normal and
malignant breast tissue and correlate this expression with potential
functional consequences, in vivo and in vitro. 
MATERIALS AND METHODS 
Patients and samples 
Random samples of normal and malignant breast tissue (formalin
fixed (n = 74) and fresh (n = 8)) from 74 patients, diagnosed with
breast cancer in 1991–1992, as well as 5 normal samples from
reduction mammoplastic operations (fresh (n = 5), fixed (n = 2)),
were obtained from the Department of Pathology, University of
Iceland. 
Normal breast epithelium and cell lines 
Tissue samples were digested overnight with 450 IU ml– 1 collage-
nase (Type 1A, C9891, Sigma, St Louis, MO), at 37˚C under
gentle rotation. The cells were seeded into culture flasks,
precoated with type I collagen (Vitrogen 100, Celtrix labs, Palo
Alto, CA) and cultured in highly supplemented serum-free
medium, CDM4 (chemically defined medium 4). This medium,
which is used to promote growth of epithelial cells and suppress
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modified Eagle’s medium (Gibco, Rockville, MD) and contains
the following additives: 100 ng ml–1 fibronectin, 2.6 ng ml–1
sodium selenite, 20 ng ml–1 EGF, 0.1 nM oestradiol, 0.5 µ g ml–1
hydrocortisone, 1 nM triiodothyronine, 25 µ g ml–1 transferrin, 
10 µ M dibutyryl cyclic AMP, 0.1 mM phosphorylethanolamine,
20  µ g ml–1 fetuin, 10 µ g ml–1 ascorbic acid, 0.01% BSA,
3.0 µ g ml–1 insulin and 10 ng ml–1 cholera toxin (all from Sigma);
75 U ml–1 penicillin and 75 µ g ml–1 streptomycin (Gibco). During
collagenase digestion, 5% fetal bovine serum was included. 
Breast cancer cell lines T47-D, MDA-MB-231, MCF-7, ZR-
75-1, normal breast cell line MCF-10A and the Jurkat T cell line
were obtained from American Type Culture Collection (ATCC,
Manassas, VA) and grown in the media recommended by ATCC.
As a positive control for surface expression of FasL, the cell lines
KFL9, a human FasL-tranfectant of human myeloid leukaemia
K562 (kindly provided by Dr D Kaplan, Cleveland, OH) (Smith 
et al, 1998) and the Jurkat variant J77 (kindly provided by Tim
Hemesath, DeCode Genetics) were used. J77 was stimulated by
incubation with OKT3 (ATCC, 5 µ g ml–1) for 30 minutes on ice,
followed by crosslinking with goat anti-mouse Ig (Sigma) at 37˚C
for 4 hours. The FasL-transfected and mock-transfected Neuro-2a
cell lines were a gift from Dr A Fontana (Zurich, Switzerland)
(Rensing-Ehl et al, 1995). Breast milk was obtained from healthy
volunteers at the department of Obstetrics and Gynecology, the
National Hospital. 
Immunohistochemistry 
Immunostaining was performed on 4 µ m thick tissue sections,
mounted on superfrosted slides (Menzel, Germany). The formalin-
fixed sections were dewaxed in xylol and rehydrated in graded
ethanol solutions. Tissue sections were then incubated in citrate
buffer (pH 6.0) for 2 × 5 min in an 850 W microwave oven. The
sections were stained with monoclonal mouse IgG1 to Fas and
FasL (Transduction Labs, Lexington, KY) and polyclonal rabbit
IgG to FasL (clone Q-20; Santa Cruz Biotech, Santa Cruz, CA).
The monoclonal antibodies detect the extracellular region of both
proteins but the polyclonal Ab detects the intracellular domain of
FasL. As a negative control, isotype matched nonspecific mouse
IgG1 (PharMingen, San Diego, CA) replaced the monoclonal Ab.
In the case of polyclonal rabbit Ab two controls were used: the
primary Ab was preincubated with control peptide or replaced by
normal rabbit serum. The antibodies were used at 2.5 µ g ml–1
(mAb) or 1 µ g ml–1 (polyclonal Ab) and incubated overnight
at RT. Binding of antibodies was detected with secondary
biotinylated Ab and streptavidin complexed with peroxidase
(StreptABComplex DUET, DAKO, Glostrup, DK) according to
the manufacturer’s protocol. Double staining with monoclonal
mouse IgG1 (1/100) to Fas (kindly provided by Dr Peter
Krammer, German Cancer Res, Heidelberg, Germany) and the
rabbit Ab to FasL, was performed on frozen tissue sections, fixed
in acetone for 10 minutes. FITC labelled swine anti-rabbit
(DAKO) and Cy5-linked goat anti-mouse (Amersham Pharmacia
Biotech Inc, Piscataway, NJ) secondary Ab was used to detect the
staining. Fas expression was detectable in tumour-infiltrating
lymphocytes (TILs) in 90% of tumour samples where as FasL was
expressed in TILs in 20% of tumours. 20 samples showing either
strong or no expression of Fas or FasL in lymphocytes were 
then stained for apoptosis. Apoptosis was evaluated by TUNEL
based assay (ApopTag Plus In Situ Detection Kit, Oncor Inc,
Gaithersburg, MD) according to the manufacturer’s protocol. Rat
mammary tissue in involution was used as a positive control
(provided with the kit). The staining was evaluated by three
independent investigators as either positive or negative. 
Isolation of RNA and RT-PCR analysis 
RNA was isolated from tissue samples and cell lines using the
TRIzol-Reagent (Life Technologies, Inc, Rockville, MD) as
described by the manufacturer. First-Strand cDNA Synthesis Kit
(Amersham) was used for reverse transcription of ca 3 µ g RNA.
Fas-specific oligonucleotides 5′ -GAA ATG AAA TCC AAA GCT
TGG 3′ (forward) and 5′ - TAA TTT AGA GGC AAA GTG GCC-
3′ (reverse) were used for Fas cDNA amplification which created
469-bp amplimer. The reaction mixture contained 1 µ l template,
0.9 mM MgCl2, 7.5 µ mol of dNTP, 10 pmol of each primer and 
0.5 U of Taq polymerase (Finnzyme, Espoo, Finland) in a volume
of 25 µ l. The thermocycler was programmed as follows: 95˚C for
2 min; 40 cycles of 95˚C for 1 min, 55˚C for 1 min, 72˚C for 
1 min; followed by 72˚C for 5 min. FasL cDNA was amplified by
specific primers 5′ -GGA TTG GGC CTG GGG ATG TTT CA-3′
(forward) and 5′ -TTG TGG CTC AGG GGC AGG TTG TTG-3′
(reverse), resulting in a 344-bp PCR product. 1–2 µ l of cDNA
template were added to 23–24-µ l reaction mixture containing 
1.5 mM MgCl2, 7.5 µ mol of dNTP, 7 pmol of each primer and 1.25 U
of Taq polymerase. Amplification proceeded as follows: 95˚C for
2 min; 40 cycles of 94˚C for 45 s, 65˚C for 45 s, 72˚C for 1 min;
72˚C for 5 min. CD3-specific oligonucleotides 5′ -GGC TGT CCT
CAT CCT GGC TAT CAT-3′ (forward) and 5′ -ACT GGT TTC
CTT GAA GGT GGC TGT-3′ (reverse) were used to amplify CD3
cDNA, creating a 515-bp PCR product. 25 µ l mixture of 1 µ l
template, 3 mM MgCl2, 10 µ mol of dNTP and 15 pmol of each
primer, was heated for 5 min at 95˚C and cooled down to 80˚C. 
0.5 U of Taq polymerase was added to the mixture and PCR
programme proceeded as follows: 40 cycles of 95˚C for 1 min,
65˚C for 1 min, 72˚C for 2 min; followed by 72˚C for 5 min.
Pyruvate dehydrogenase (PDH, positive control) was amplified by
PDH-specific primers 5′ -GGT ATG GAT GAG GAG CTG GA-3′
(forward) and 5′ -CTT CCA CAG CCC TCG ACT AA-3′
(reverse); resulting in a 102 bp amplimer. The reaction mixture
contained 1 µ l template, 1.5 mM MgCl2, 7.5 µ mol of dNTP,
7 pmol of each primer and 0.5 U of Taq polymerase in 25-ml
volume. PCR conditions were as follows: 95˚C for 2 min;
35 cycles of 95˚C for 45 s, 59˚C for 40 s, 72˚C for 1 min; followed
by 5 min at 72˚C. PCR products were separated by electrophoresis
on a 7.5% polyacrylamide gel, stained with ethidium bromide and
visualized by UV. 
Western blotting 
Normal breast cells in culture or cell lines were lysed on ice in
lysis buffer (10 mM Tris-HCL, pH 7.4, 150 mMNaCl, 5 mM
EDTA, 10% glycerol, 1% Triton-X100, 10 µ g ml–1 aprotinin, 
1 mM PMFS, 1 mM Na-Orthovanadate, 1 mM leupeptin).
Insoluble material was pelleted for 5 minutes at 14000 g and the
cell lysate was mixed with an equal volume of 2 × SDS sample
buffer (4% SDS, 100 mM Tris, pH 6.8, 200 mM DTT, 0.2%
bromophenol blue, 20% glycerol) and loaded onto 10% acryl-
amide gels at the equivalent of 1 × 106 cells lane–1. After electro-
phoresis the proteins were transferred to Immun-Blot PVDF
membrane (BioRad, Hercules, California). The blots were blocked
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blots were tested with two primary FasL Abs (Transduction Labs.
clone 33, PharMingen clone G247-4), followed by a horse-
radish peroxidase-conjugated secondary Ab (Amersham)
Immunoreactive bands were visualized by enhanced chemilumi-
nescence (Amersham). 
FACS analysis 
Before staining for surface bound Fas and FasL, cells were grown
for 24 hours in the presence of 10 µ M matrix metalloprotease
inhibitor (MMPI KB8301, PharMingen) to prevent shedding of
soluble FasL. Adherent cells were detached with 2.5 mM EDTA in
PBS, washed twice in RPMI containing MMPI and dissolved in
the same at a concentration of 2 × 106 cells ml–1. 50 µ l of cell
suspension were stained with FITC-conjugated Fas antibody
(clone DX2, DAKO) or biotinylated FasL antibody (clone NOK-1,
PharMingen), followed by FITC-conjugated Streptavidin (Becton
Dickinson, San Jose, CA). For detection of intracellular Fas 
and FasL, 1 × 106 cells were fixed and permeabilized using the
Cytofix/Cytoperm kit (PharMingen), and stained with antibodies
against Fas (clone 13, Transduction Labs.) or FasL (Transduction
Labs, clone 33, PharMingen, clone G247-4), followed by FITC-
conjugated anti-mouse IgG Ab (Becton Dickinson). Non-specific,
isotype-matched primary Abs (PharMingen) were used as negative
control. Apoptosis of Jurkat cells was detected using recombinant
human Annexin V (CALTAG Laboratories, Burlingame, CA) as
directed by the manufacturer. Analysis was performed on a
FACScan flow cytometer (Becton Dickinson). 
Co-culture of normal and malignant breast epithelium
and Jurkat cells 
Breast cancer cell lines, normal breast epithelial cells and trans-
fected Neuro-2a cells were seeded in 24-well tissue culture plates
and grown until confluent at which time the wells contained about
8 × 105 effector cells. MMPI (10 µ M) was kept in the culture for
the last 24 hours before use. One half of the wells were fixed with
2% paraformaldehyde, followed by extensive washing with PBS.
2.5 × 104 Jurkat cells were added to each well in a volume of 
0.5 ml and the cells were co-cultured for 24 hours. To some wells,
blocking Fas Ab (clone ZB4, 250 ng ml–1, MBL, Watertown, MA)
and/or activating Fas Ab (clone CH11, 50 ng ml–1, Oncor) were
added. The Jurkat cells were analysed with respect to apoptotic
and dead cells, using recombinant Annexin V and PI. All wells
were set up in triplicates. After testing apoptosis at various time-
points, cocultures with breast cells were harvested after 24 hours
and cocultures on the FasL-transfected cell line after 4 hours. 
Breast cell culture supernatants were concentrated 10 × using 
a filter device (Amicon) and assayed for the presence of soluble
FasL (sFasL) using a sFasL-specific ELISA kit (MBL). 
RESULTS 
Fas and FasL are co-expressed in normal and
malignant breast tissue 
Several reports have documented downregulation of Fas and
upregulation of FasL in human tumours. To examine possible
changes in Fas/FasL expression in malignant breast tissue, tumour
samples from 74 breast cancer patients were evaluated using
immunoperoxidase staining of formalin fixed tissue (Figure 1 D, E).
71 of these samples showed positive staining for Fas and FasL, 
the remaining samples were inconclusive. The same pattern of
staining was seen in normal breast epithelium, i.e. co-expression
of Fas and FasL in luminal cells (Figure 1 A, B, G, H). Staining
with monoclonal and polyclonal anti-FasL was concordant. FasL
is therefore not upregulated nor is Fas downregulated in breast
cancer compared to normal tissue. 
To establish that the observed co-expression of Fas and FasL in
normal and malignant breast tissue was not due to non-specific
binding of the antibodies, RT-PCR analysis was performed on
RNA isolated from normal breast epithelium in culture, fresh-
frozen normal breast tissue, breast tumour samples and all breast
cell lines (Figure 2). All the samples expressed both Fas and 
FasL mRNA (Figure 2A, B). In order to assess whether Fas 
and FasL detected in RNA from fresh tissue could have come from
infiltrating lymphocytes, control RT-PCR was performed with
primers specific for CD3 (Figure 2C). No CD3 bands were seen in
any of the fresh-frozen breast tissue preparations, whereas strong
amplification of CD3 mRNA was seen in Jurkat T cells and
peripheral blood. It is possible that FasL could haemopoetic come
from CD3 negative cells. 
Finally, Western blot of total cell lysate from cultured breast
epithelium from three different individuals, as well as all above
mentioned breast cancer cell lines, was positive for Fas and FasL
protein using antibodies from two different manufacturers (data
not shown). 
FasL expression in normal and malignant breast
epithelium is intracellular 
FasL must be present on the cell surface to induce apoptosis in
Fas-sensitive cells. The co-expression of Fas and FasL in the same
cells implies that there must be a mechanism that prevents self
destruction of the cells, i.e. either Fas must be insensitive to 
activation by FasL or FasL is not present on the cell surface. To
examine the second possibility, intra- and extracellular Fas and
FasL expression on various cell types was analysed by flow
cytometry. Figure 3 shows representative results from these experi-
ments. Normal cells, T47D and MCF-10A expressed Fas on the
surface of the cells, whereas other cell lines did not. However, in
concordance with the RNA analysis and Western blotting, Fas was
detected intracellularly in all the breast cells tested. FasL was
neither detected on the cell surface of normal breast epithelial cells
in culture nor any of the cell lines. However, after permeabiliza-
tion, all of these cell types showed clear positive staining for FasL,
using two different antibodies. Thus, FasL seems to be confined to
intracellular compartments under normal culture conditions. 
Fas-sensitive Jurkat cells are not killed by breast cells 
It is possible that functional FasL is expressed on the surface of
breast cells in such low quantity that it is not detectable by flow
cytometry. To test whether FasL-expressing breast epithelial cells
can induce apoptosis in Fas-sensitive Jurkat cells, these two cell
types were co-cultured in the presence or absence of blocking Fas
antibody (Figure 4). Neither normal epithelial cells nor malignant
cell lines induced Fas-mediated apoptosis in Jurkat cells. Addition
of metalloprotease inhibitor to the cultures or fixing of the breast
cells with paraformaldehyde did not alter the results. Finally, to
examine whether sFasL was secreted from the breast cell, culture
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concentrated 10 × and analysed by sFasL-specific ELISA. sFasL
was not detected in any of the culture supernatants (data not
shown). 
Analysis of apoptosis in breast tumours 
Our results suggest that FasL expression may not be a factor in
protecting breast tumour cells from the immune system, i.e. as
long as FasL expression is intracellular it can exert little effect on
incoming lymphocytes. As a final step in our analysis, we evalu-
ated apoptosis in 20 paraffin-embedded breast tumour samples
that had detectable lymphocytic infiltrates and had been stained
previously for Fas and FasL (Figure 1F). A few apoptotic lympho-
cytes were detected in all samples; however, none of the samples
showed marked apoptosis in areas where tumour and lymphocytes
meet. Thus, in situ analysis of apoptosis in breast tumours does
not indicate that tumour cells are causing apoptosis in adjacent
lymphocytes or vice versa. 
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Figure 1 Staining of Fas (A and D) and FasL (B and E) in formalin fixed normal (A and B) and malignant (D and E) breast epithelium (monoclonal Ab). Fas
and FasL expression is not different in normal and tumour tissue. Co-expression on the same cells is shown by immunofluorescence costaining of Fas (G) and
FasL (H) in cryosections of normal epithelium. Negative control (unspecific mouse IgG1) is shown in C. Apoptosis (F) is not increased in tumour infiltrating
lymphocytes nor in malignant cells adjacent to the lymphocytes. Positive control (rat breast epithelium in involution) is shown in I. Lymphocytes: smaller cells to
the left in D–F. (Original magnification: A–F, I: 250 × ; G–H: 1250× ) DISCUSSION 
Breast tumours often contain large infiltrates of lymphocytes but
the functional or prognostic significance of these cells is not clear
despite decades of study (Stewart and Tsai, 1993; O’Sullivan and
Lewis, 1994). Although it has been possible to isolate T cells that
have cytolytic activity against the tumour in vitro, these cells seem
to be unable to control tumour growth in vivo (Whiteside et al,
1986; Jerome et al, 1991). Several reasons have been suggested for
this failure of the immune system; downregulation of MHC anti-
gens on the tumour, secretion of immunosuppressive substances
by tumour cells or lack of costimulation, resulting in anergy of T
lymphocytes, can all play a role in the tumour’s escape from
immune attack (Baskar et al, 1996; Chouaib et al, 1997; Garrido 
et al, 1997). 
The discovery that a subset of primary tumours, as well as cell
lines, may reduce their expression of Fas and start to express FasL
suggested yet another way for solid tumours to defend themselves
against activated lymphocytes (O’Connell et al, 1999a). FasL on
tumour cell lines and tumour tissue sections, can cause apoptosis
in Fas-sensitive Jurkat cells (Strand et al, 1996; Niehans et al,
1997) and one report suggested an increase in apoptosis of tumour-
infiltrating lymphocytes (TIL) in FasL-expressing oesophageal
carcinoma (Bennett et al, 1998). It is worth noting that some
controversy remains about FasL expression in melanomas (Hahne
et al, 1996; Chappell et al, 1999). We examined Fas and FasL
expression in both normal and malignant breast tissue and found
that all tumour samples that showed conclusive staining, co-
expressed both receptors also shown by other recent study
(O’Connell et al, 1999b). However, unexpectedly, we found that
normal breast epithelium also expresses both receptors; therefore,
FasL expression on cancerous tissue was not an adaptation to
evade an immune attack. Furthermore, Fas is not downregulated in
breast cancer which is in accord with a previous report (Leithäuser
et al, 1993). This pattern of expression was further confirmed by
Western blot and RT-PCR. FACS-analysis of normal and cancer
FasL and apoptosis in breast cancer 1719
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Figure 3 Flow cytometry analysis of Fas and FasL expression in normal
epithelial cells in culture and a representative cell line, MDA-MB-231. FasL
was detected on the surface of the Jurkat variant J77 after CD3 crosslinking
(non-shaded curve) and on the KFL9 cell line (data not shown) 
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Figure 2 RT-PCR analysis of FasL, Fas, CD3 and pyruvate dehydrogenase
expression in various breast cells. Samples are ordered in the following way:
1, negative control (no cDNA); 2, ZR-75-1; 3, MCF-10A; 4, T47D; 5, cultured
fibroblasts; 6, Jurkat cells; 7, peripheral blood mononuclear cells (PBMC); 
8, normal breast tissue (primary culture); 9, normal breast tissue (frozen); 
10, tumour breast tissue (frozen); 11, DNA ladder. Very faint band was
detected for: FasL in T47D and normal cultured cells and Fas in tumour
tissue cells demonstrated that FasL is only expressed intracellularly thus
unable to kill neighbouring cells. In co-culture, neither normal nor
malignant breast epithelium, induced apoptosis in Fas-sensitive
Jurkat cells. Similar results were published by Kontny et al who
found that Ewing sarcoma cells only expressed FasL intracellu-
larly and did not induce apoptosis in Jurkat cells (Kontny et al,
1998). If sFasL is released by the tumour cells this could prevent
killing of Fas-positive T-lymphocytes (O’Connell et al, 1999a) but
sFasL was not detected in culture supernatants from breast cells.
When the tissue samples were stained for apoptosis, we found no
indication that the tumour was causing apoptosis in infiltrating
lymphocytes or vice versa. Our conclusion is, therefore, that
lymphocytes and cancerous cells coexist in the tumours. 
Our data raise a number of questions about the role of FasL
expression in normal breast epithelium. The role of Fas/FasL in
cellular homeostasis is well known in the immune system but not
in epithelial tissue. Co-expression of Fas and FasL has been
reported in other epithelial tissues, especially at sites of rapid
turnover, e.g. in colon (Iwamoto et al, 1996; Xerri et al, 1997). The
breast is a site of a rapid turnover of cells, through each menstrual
cycle, lactation and involution (Russo and Russo, 1987). Thus, Fas
and FasL might play a role in keeping the finely tuned balance
between cellular proliferation and cell death in the breast.
Interestingly, a recent report demonstrated the existence of sFasL
and sFas in breast milk (Srivastava and Srivastava, 1999),
suggesting that these receptors do have a functional role in the
normal physiology of the breast. 
We conclude that both normal and malignant breast tissue
express both Fas and FasL, but functional FasL is not present on
the surface of the cells and therefore has no effect on the prognosis
of the breast cancer patients. Furthermore, FasL expression on
breast tumour cells does not seem to cause apoptosis in neigh-
bouring lymphocytes. Our results do not support an active role for
FasL in the escape of breast tumours from immune attack. 
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